ArticleISME communications2022
Changes in the skin microbiome associated with squamous cell carcinoma in transplant recipients.
Article in ISME communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Poly(3-hydroxybutyrate)-Based Biomimetic Materials Encapsulated with Amide Derivatives of Chlorin-e6 for Advanced Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- Actinic Keratosis at the Crossroads of Inflammation and Cutaneous Dysbiosis.Dermatology and therapy · 2026Review
- Preliminary characterization of the skin microbiota in basal cell carcinoma: An exploratory pilot study in Korean patients.Journal of microbiology (Seoul, Korea) · 2026Article
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage.Pigment cell & melanoma research · 2025Review
- Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs.mSphere · 2024Article
- Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies.Microbiology spectrum · 2023Article
- Cutaneous Surgical Wounds Have Distinct Microbiomes from Intact Skin.Microbiology spectrum · 2023Article
- TargetingFrontiers in oncology · 2023Article
- Review
- Skin Cancer-AssociatedCancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Actinic keratoses (AK) arise in severely photo-damaged skin and can progress to squamous cell carcinomas (SCC). AK and SCC are common in Caucasian populations, and immunosuppressed individuals have a markedly higher risk of developing SCC. An overabundance of Staphylococcus aureus has been reported in AK and SCC lesions of immunocompetent individuals, however, the AK/SCC microbiome in immunosuppressed cohorts has not been investigated. Here, the microbial profile and bacterial load of AK, SCC and control skin swabs from 32 immunosuppressed organ transplant recipients were characterised via SSU rRNA gene sequencing and qPCR, and compared to a previously described immunocompetent cohort. Although the taxonomic composition of skin swab samples was mostly subject-specific, significant differences were observed between control skin, AK, and SCC in both cohorts. Surface bacterial load was increased and alpha diversity decreased in AK and SCC compared to control skin due to an increased abundance of Staphylococcus species and relative decrease of skin commensals. Staphylococcus epidermidis predominated on SCC from transplant recipients in contrast to SCC of immunocompetent subjects dominated by S. aureus. In conclusion, AK and SCC of immunosuppressed and immunocompetent subjects present with distinctive microbial dysbioses, which may be relevant to SCC pathogenesis and progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.